Nasdaq1 个月
AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering
Jan. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k ...